Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
51.5 (1y: +24%)
Market Cap 64.71 B P/E(ttm) 11.40
Enterprise Value 66.97 B P/B 2.70
AZN- NYSE (USA)
AstraZeneca PLC
  • Currently 2.5/5
Business Predictability Rank: 2.5-Star (On Watch)
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$51.50
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.827
AZN's Cash to Debt is ranked lower than
72% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.36 vs. AZN: 0.827 )
AZN' s 10-Year Cash to Debt Range
Min: 0.39   Max: 8.68
Current: 0.83
0.39
8.68
Equity to Asset -0.049
AZN's Equity to Asset is ranked lower than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.52 vs. AZN: -0.049 )
AZN' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.45
Current: -0.05
-0.14
0.45
Interest Coverage 18.9
AZN's Interest Coverage is ranked lower than
73% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10000.00 vs. AZN: 18.9 )
AZN' s 10-Year Interest Coverage Range
Min: 8   Max: No Debt
Current: 18.9
F-Score: 4
Z-Score: 2.77
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 29.10
AZN's Operating margin (%) is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.70 vs. AZN: 29.10 )
AZN' s 10-Year Operating margin (%) Range
Min: 1.5   Max: 38.1
Current: 29.1
1.5
38.1
Net-margin (%) 22.5
AZN's Net-margin (%) is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. AZN: 22.5 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.4   Max: 29.7
Current: 22.5
6.4
29.7
ROE (%) 26.5
AZN's ROE (%) is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. AZN: 26.5 )
AZN' s 10-Year ROE (%) Range
Min: 11.1   Max: 42.9
Current: 26.5
11.1
42.9
ROA (%) 11.8
AZN's ROA (%) is ranked higher than
90% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. AZN: 11.8 )
AZN' s 10-Year ROA (%) Range
Min: 5.8   Max: 20.2
Current: 11.8
5.8
20.2
ROC (Joel Greenblatt) (%) 125.20
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.40 vs. AZN: 125.20 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.7   Max: 160.9
Current: 125.2
2.7
160.9
Revenue Growth (%) -0.5
AZN's Revenue Growth (%) is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. AZN: -0.5 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -0.5   Max: 11.4
Current: -0.5
-0.5
11.4
EBITDA Growth (%) -2.6
AZN's EBITDA Growth (%) is ranked higher than
89% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.35 vs. AZN: -2.6 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -24.2   Max: 63
Current: -2.6
-24.2
63
EPS Growth (%) -1
AZN's EPS Growth (%) is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. AZN: -1 )
AZN' s 10-Year EPS Growth (%) Range
Min: -25.4   Max: 26.5
Current: -1
-25.4
26.5
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AZN Guru Trades in Q2 2012

HOTCHKIS & WILEY 1,912,816 sh (New)
Jim Simons 1,870,500 sh (+15.04%)
Joel Greenblatt 85,698 sh (+14.94%)
Manning & Napier Advisors, Inc 467,211 sh (+14.87%)
Vanguard Health Care Fund 14,181,500 sh (unchged)
John Hussman 2,517,000 sh (unchged)
Ken Fisher Sold Out
Charles Brandes 2,612,117 sh (-6.21%)
David Dreman 423,269 sh (-8.52%)
Steven Cohen 12,994 sh (-94.54%)
» More
Q3 2012

AZN Guru Trades in Q3 2012

Joel Greenblatt 122,294 sh (+42.7%)
Jim Simons 2,513,100 sh (+34.35%)
HOTCHKIS & WILEY 1,977,316 sh (+3.37%)
Manning & Napier Advisors, Inc 478,247 sh (+2.36%)
Charles Brandes Sold Out
Vanguard Health Care Fund 13,881,500 sh (-2.12%)
John Hussman 2,017,000 sh (-19.86%)
David Dreman 320,376 sh (-24.31%)
Steven Cohen 8,531 sh (-34.35%)
» More
Q4 2012

AZN Guru Trades in Q4 2012

Charles Brandes 2,188,735 sh (New)
Pioneer Investments 526,207 sh (New)
Manning & Napier Advisors, Inc 481,862 sh (+0.76%)
Steven Cohen Sold Out
Jim Simons 2,502,500 sh (-0.42%)
HOTCHKIS & WILEY 1,965,216 sh (-0.61%)
John Hussman 1,523,000 sh (-24.49%)
Joel Greenblatt 83,972 sh (-31.34%)
David Dreman 152,504 sh (-52.4%)
» More
Q1 2013

AZN Guru Trades in Q1 2013

NWQ Managers 78,400 sh (New)
Steven Cohen 8,894 sh (New)
Jim Simons 3,627,000 sh (+44.94%)
Pioneer Investments 761,116 sh (+44.64%)
Joel Greenblatt 93,261 sh (+11.06%)
HOTCHKIS & WILEY 2,138,888 sh (+8.84%)
David Dreman 164,649 sh (+7.96%)
Manning & Napier Advisors, Inc 509,072 sh (+5.65%)
Charles Brandes 2,039,355 sh (-6.82%)
John Hussman 932,000 sh (-38.8%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -38.8%0.74%$44.67 - $50.06 $ 51.59%932000
Charles Brandes 2012-12-31 New Buy1.2%$44.34 - $48.9 $ 51.510%2188735
John Hussman 2012-12-31 Reduce -24.49%0.56%$44.34 - $48.9 $ 51.510%1523000
David Dreman 2012-12-31 Reduce -52.4%0.2%$44.34 - $48.9 $ 51.510%152504
Joel Greenblatt 2012-12-31 Reduce -31.34%0.12%$44.34 - $48.9 $ 51.510%83972
Charles Brandes 2012-09-30 Sold Out 1.2%$44.91 - $48.35 $ 51.510%0
Joel Greenblatt 2012-09-30 Add 42.7%0.12%$44.91 - $48.35 $ 51.510%122294
David Dreman 2012-09-30 Reduce -24.31%0.11%$44.91 - $48.35 $ 51.510%320376
Joel Greenblatt 2012-03-31 Add 66.8%0.12%$44.18 - $48.58 $ 51.520%74557
Joel Greenblatt 2011-12-31 New Buy0.25%$42.53 - $49.89 $ 51.512%44699
Joel Greenblatt 2011-06-30 Sold Out 0.33%$46.6 - $52.4 $ 51.53%0
Bruce Berkowitz 2011-06-30 Sold Out 0.05%$46.6 - $52.4 $ 51.53%0
Joel Greenblatt 2011-03-31 Reduce -51.77%0.35%$45.4 - $49.38 $ 51.58%23900
Bruce Berkowitz 2011-03-31 New Buy0.05%$45.4 - $49.38 $ 51.58%155000
Joel Greenblatt 2010-12-31 New Buy0.75%$45.8 - $53.5 $ 51.54%49550
John Hussman 2010-06-30 Add 24.98%0.61%$40.91 - $48.74 $ 51.517%3753000
David Dreman 2010-06-30 Add 20.9%0.1%$40.91 - $48.74 $ 51.517%484949
John Hussman 2010-03-31 Add 15.5%0.32%$43.05 - $50.4 $ 51.513%3003000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about AstraZeneca PLC

Global Malaise Not Affecting These Countries (Or Companies)
March 10, 2013
Yes, there has been a global malaise that began in 2008. (Much earlier, actually, but 2008 is when someone noticed that the drinks were being paid for with Monopoly money.) The U.S. Federal Reserve had been spiking the punch bowl and refreshing it every time the drunks started to sober up. When the nation responsible for more world trade and consumption than any other gets a really bad hangover, it's tough for the rest of the crowd not to be affected. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 11.40
AZN's P/E(ttm) is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.76 vs. AZN: 11.40 )
AZN' s 10-Year P/E(ttm) Range
Min: 5.74   Max: 32.5
Current: 11.4
5.74
32.5
P/B 2.70
AZN's P/B is ranked higher than
55% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. AZN: 2.70 )
AZN' s 10-Year P/B Range
Min: 2.26   Max: 9.82
Current: 2.7
2.26
9.82
P/S 2.39
AZN's P/S is ranked higher than
54% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. AZN: 2.39 )
AZN' s 10-Year P/S Range
Min: 1.32   Max: 6.54
Current: 2.39
1.32
6.54
PFCF 23.20
AZN's PFCF is ranked higher than
60% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. AZN: 23.20 )
AZN' s 10-Year PFCF Range
Min: 6.44   Max: 54.92
Current: 23.2
6.44
54.92
EV-to-EBIT 9
AZN's EV-to-EBIT is ranked higher than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.70 vs. AZN: 9 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.2   Max: 155
Current: 9
4.2
155
PEG 4.2
AZN's PEG is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. AZN: 4.2 )
AZN' s 10-Year PEG Range
Min: 0.16   Max: 13.46
Current: 4.2
0.16
13.46
Shiller P/E 9.4
AZN's Shiller P/E is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.12 vs. AZN: 9.4 )
AZN' s 10-Year Shiller P/E Range
Min: 7.47   Max: 18.25
Current: 9.4
7.47
18.25

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 5.44
AZN's Dividend Yield is ranked higher than
99% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. AZN: 5.44 )
AZN' s 10-Year Dividend Yield Range
Min: 1.25   Max: 7.18
Current: 5.44
1.25
7.18
Dividend Payout 0.6185
AZN's Dividend Payout is ranked higher than
72% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.86 vs. AZN: 0.6185 )
AZN' s 10-Year Dividend Payout Range
Min: 0.55   Max: 1.6
Current: 0.62
0.55
1.6
Dividend growth (3y) 8.5
AZN's Dividend growth (3y) is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.95 vs. AZN: 8.5 )
AZN' s 10-Year Dividend growth (3y) Range
Min: 0.4   Max: 20.1
Current: 8.5
0.4
20.1
Yield on cost (5-Year) 9.35
AZN's Yield on cost (5-Year) is ranked higher than
99% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. AZN: 9.35 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.16   Max: 12.43
Current: 9.35
2.16
12.43
Share Buyback Rate 3.4
AZN's Share Buyback Rate is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.00 vs. AZN: 3.4 )
AZN' s 10-Year Share Buyback Rate Range
Min: 3.4   Max: 0.6
Current: 3.4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 8.7
AZN's Price/Net Current Asset Value is ranked higher than
65% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. AZN: 8.7 )
AZN' s 10-Year Price/Net Current Asset Value Range
Min: 6.8   Max: 23.6
Current: 8.7
6.8
23.6
Price/DCF (Projected) 0.8
AZN's Price/DCF (Projected) is ranked higher than
69% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. AZN: 0.8 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 2.6
Current: 0.8
0.6
2.6
Price/Median PS Value 1.1
AZN's Price/Median PS Value is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.70 vs. AZN: 1.1 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.5
Current: 1.1
0.7
2.5
Earnings Yield (Greenblatt) 11.10
AZN's Earnings Yield (Greenblatt) is ranked higher than
97% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. AZN: 11.10 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 23.5
Current: 11.1
0.6
23.5
Forward Rate of Return (Yacktman) 11.14
AZN's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.82 vs. AZN: 11.14 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.6   Max: 57.5
Current: 11.14
-6.6
57.5

Business Description

AstraZeneca PLC is engaged in the global, prescription-based biopharmaceutical business. Its pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. It focuses on six therapy areas of healthcare such as Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation. The company has operations in the United Kingdom, Continental Europe, The Americas, Asia, Africa, and Australasia.
Company Website
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:AZN.Sweden, AZN.UK, ZEGA.Germany, ZEG.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial